Last update 06 Jun 2025

MORAb-028

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
MORAB 028, MORAB-028, MT 228
Target
GD2
Action
inhibitors
Mechanism
GD2 inhibitors(Disialoganglioside GD2 inhibitors)
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal Diseases
Active Indication-
Inactive Indication
Malignant melanoma, metastaticMetastatic melanoma
Originator Organization
Micromet AG
Active Organization-
Inactive Organization
Morphotek, Inc.Morphotek, Inc.
License Organization-
Drug Highest PhaseDiscontinuedPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with MORAb-028
NCT01212276
/ TerminatedPhase 1
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Radiologic Distribution of Ascending Single-Dose Radiolabeled MORAb-028 in Subjects With Metastatic Melanoma
NCT01123304
/ TerminatedPhase 1
A Phase 1 Clinical Trial of Intra-Tumoral Injection of Human IgM Monoclonal Antibody (MORAb-028) to the Ganglioside GD2 in Subjects With Injectable Metastatic Melanoma
100 Clinical Results associated with MORAb-028
Login to view more data
100 Translational Medicine associated with MORAb-028
Login to view more data
100 Patents (Medical) associated with MORAb-028
Login to view more data
100 Deals associated with MORAb-028
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Malignant melanoma, metastaticPhase 1
United States
Morphotek, Inc.Morphotek, Inc.
01 Dec 2010
Metastatic melanomaPhase 1
United States
Morphotek, Inc.Morphotek, Inc.
01 May 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free